PTN stock forecast
Our latest prediction for Palatin Technologies, Inc.'s stock price was made on the Aug. 2, 2019 when the stock price was at 0.84$.
In the short term (2weeks), PTN's stock price should outperform the market by 4.79%. During that period the price should oscillate between -5.45% and +15.04%.
In the medium term (3months), PTN's stock price should outperform the market by 7.03%. During that period the price should oscillate between -12.03% and +42.76%.Get email alerts
Create a solid portfolio with PTN
About Palatin Technologies, Inc.
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
At the moment the company generates 21M USD in revenues.
On its last earning announcement, the company reported a loss of -0.03$ per share.
The book value per share is 0.13$
Three months stock forecastAug. 2, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|